To investigate the prognostic value of urokinase-type plasminogen activator (uPA) and its inhibitor, type-1 plasminogen activator inhibitor (PAI-1), in differentiated thyroid cancer.
Study Design
Prospective cohort study.
Setting
University hospital.
Subjects and Methods
Cytosolic concentrations of uPA and PAI-1 were determined in 105 patients with differentiated thyroid carcinoma and normal matched tissues using an enzyme-linked immunoassay (ELISA).
Results
Both uPA and PAI-1 concentrations were significantly higher in differentiated thyroid tumors (uPA = 0.509 ± 0.767 and PAI-1 = 6.337 ± 6.415 ng/mg) compared to normal tissues (uPA = 0.237 ± 0.051, P < .001; PAI-1 = 2.368 ± 0.418 ng/mg, P < .001). uPA and PAI-1 were significantly higher if extrathyroidal invasion (uPA, P = .015; PAI-1, P < .001) or distant metastasis (PAI-1 P < .001) was present, as well as in tumors whose size exceeded 1 cm in diameter (uPA, P = .002; PAI-1, P = .001). Survival analysis revealed the significant impact of both uPA and PAI-1 on progression-free survival (PFS) (82.22 vs 49.478 months for patients with low and high uPA, respectively, P < .001; 87.068 vs 44.964 months for patients with low and high PAI-1, respectively, P < .001). Univariate analysis showed that gender, tumor size, tumor grade, extrathyroid invasion, local lymph node involvement, distant metastasis, uPA, and PAI-1 were significant predictors of PFS. However, multivariate analysis identified only distant metastasis and tumor tissue uPA and PAI-1 as independent prognostic factors.
Conclusion
These findings indicate that high uPA and PAI-1 levels represent independent unfavorable prognostic factors in patients with differentiated thyroid carcinoma.
JemalASiegelRWardE. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2.
SiegelRNaishadhamDJemalA. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
3.
RuggeriRMCampennìABaldariSTrimarchiFTrovatoM. What is new on thyroid cancer biomarkers. Biomark Insights. 2008;3:237-252.
4.
AndreasenPAKjöllerLChristensenLDuffyMJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer. 1997;72:1-22.
5.
KwaanHCMcMahonB. The role of plasminogen-plasmin system in cancer. Cancer Treat Res. 2009;148:43-66.
6.
DassKAhmadAAzmiASSarkarSHSarkarFH. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev. 2008;34:122-136.
7.
SchmittMHarbeckNThomsenC. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost. 1997;78:285-296.
8.
EORTC. Breast Cancer Cooperative Group Revision of the standards for the assessment of hormone receptors in human breast cancer. Eur J Cancer. 1980;16:1513-1515.
9.
JanickeFPacheLSchmittM. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res. 1994;54:2527-2530.
10.
DuffyMJ. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level I evidence studies. Clin Chem. 2002;48(8):1194-1197.
AnneckeKSchmittMEulerU. uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. Adv Clin Chem. 2008;45:31-45.
13.
LamyPJRomieuGJacotW. uPA/PAI-1: a tool for breast cancer treatment individualization. Biology, clinical implications and quantification assays. Bull Cancer. 2010;97:341-348.
14.
NekardaHSchmittMUlmK. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res. 1994;54:2900-2907.
15.
FujiTObaraTTannoSUraHKohgoY. Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas. Hepatogastroenterology. 1999;46:2299-2308.
16.
SaldenMSplinterTAPetersHA. The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group. Ann Oncol. 2000;11:327-332.
17.
PedersenHBrunnerNFrancisD. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res. 1994;54:4671-4675.
18.
HofmannRLehmerABureschMHartungRUlmK. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer. 1996;78:487-492.
19.
GuptaALotanYAshfaqR. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Eur Urol. 2009;55:1124-1134.
20.
KonecnyGUntchMPihanA. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. Clin Cancer Res. 2001;7:1743-1749.
21.
SteinerEPollowKHasencleverD. Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1(PAI-1) for prognosis in endometrial cancer. Gynecol Oncol. 2008;108:569-576.
22.
TaubertHWürlPGreitherT. Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients. Br J Cancer. 2010;102:731-737.
23.
StabucBMarkovićJBartenjevIVrhovecIMedvedUKocijančićB. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma. Oncol Rep. 2003;10:635-639.
24.
SmithJWvan der PluijmGRomijnHALöwikCWMorreauHGoslingsBM. Degradation of extracellular matrix by metastatic follicular thyroid carcinoma cell lines: role of the plasmin activation system. Thyroid. 1999;9:913-919.
25.
ItoYTakedaTKobayashiT. Plasminogen activation system is active even in thyroid tumors: an immunohistochemical study. Anticancer Res. 1996;16:81-90.
26.
ZanettiAStoppacciaroAMarzulloA. Expression of Met protein and urokinase-type plasminogen activator receptor (uPA-R) in papillary carcinoma of the thyroid. J Pathol. 1998;186:287-291.
27.
ChuQDHurdTCHarveyS. Overexpression of urinary plasminogen activator (uPA) protein and mRNA in thyroid carcinogenesis. Diagn Mol Pathol. 2004;13:241-246.
28.
KimSJShibaETaguchiT. uPA receptor expression in benign and malignant thyroid tumors. Anticancer Res. 2002;22:387-393.
29.
UlisseSBaldiniETollerM. Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas. Eur J Cancer. 2006;42:2631-2638.
30.
UlisseSBaldiniESorrentiS. High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2011;96:504-508.
31.
Horvatic HercegGHercegDKralikMBence-ZigmanZTomic-BrzacHKulicA. Urokinase-type plasminogen activator and its inhibitor in thyroid neoplasms: a cytosol study. Wien Klin Wochenschr. 2006;118:601-609.
32.
MazzaferriELKloosRT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447-1463.
33.
PaciniFEliseiRCapezzoneM. Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients. Thyroid. 2001;11:877-881.
34.
SugitaniIKasaiNFujimotoYYanagisawaA. A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery. 2004;135:139-148.
35.
ChowSMLawSCChanJKAuSKYauSLauWH. Papillary microcarcinoma of the thyroid—prognostic significance of lymph node metastasis and multifocality. Cancer. 2003;98:31-40.
36.
HughesCJShahaARShahJPLoreeTR. Impact of lymph node metastasis in differentiated carcinoma of the thyroid: a matched pair analysis. Head Neck. 1996;18:127-132.
37.
ShahaAR. Controversies in the management of thyroid nodule. Laryngoscope. 2000;110:183-193.
JukkolaABloiguREbelingTSalmelaPBlancoG. Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications. Endocr Relat Cancer. 2004;11:571-579.
40.
SoylukOSelcukbiricikFErbilYBozboraAKapranYOzbeyN. Prognostic factors in patients with papillary thyroid carcinoma. J Endocrinol Invest. 2008;31:1032-1037.
41.
VerburgFAMäderULusterMReinersC. Histology does not influence prognosis in differentiated thyroid carcinoma when accounting for age, tumour diameter, invasive growth and metastases. Eur J Endocrinol. 2009;160:619-624.
42.
UlisseSBaldiniESorrentiSD’ArmientoM. The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targets. 2009;9:32-71.
43.
MekkawyAHMorrisDLPourgholamiMH. Urokinase plasminogen activator system as a potential target for cancer therapy. Future Oncol. 2009;5:1487-1499.
44.
NowickiTSKummerNTIacobC. Inhibition of uPAR and uPA reduces invasion in papillary thyroid carcinoma cells. Laryngoscope. 2010;120:1383-1390.
